1. Home
  2. ABUS vs THFF Comparison

ABUS vs THFF Comparison

Compare ABUS & THFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.69

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo First Financial Corporation Indiana

THFF

First Financial Corporation Indiana

HOLD

Current Price

$74.46

Market Cap

930.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
THFF
Founded
2005
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
930.9M
IPO Year
2008
1995

Fundamental Metrics

Financial Performance
Metric
ABUS
THFF
Price
$4.69
$74.46
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
$5.00
★ $62.00
AVG Volume (30 Days)
★ 4.7M
90.6K
Earning Date
05-14-2026
04-28-2026
Dividend Yield
N/A
★ 3.46%
EPS Growth
55.26
★ 67.00
EPS
0.84
★ 3.58
Revenue
★ $14,083,000.00
N/A
Revenue This Year
N/A
$17.88
Revenue Next Year
$239.71
$4.03
P/E Ratio
★ $5.71
$20.73
Revenue Growth
★ 128.21
N/A
52 Week Low
$3.50
$51.21
52 Week High
$5.45
$84.17

Technical Indicators

Market Signals
Indicator
ABUS
THFF
Relative Strength Index (RSI) 37.59 32.39
Support Level $4.42 $64.54
Resistance Level $4.81 $75.61
Average True Range (ATR) 0.09 1.58
MACD -0.05 -0.26
Stochastic Oscillator 16.48 2.39

Price Performance

Historical Comparison
ABUS
THFF

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About THFF First Financial Corporation Indiana

First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.

Share on Social Networks: